Delfi Diagnostics Inc (Delfi) is a biotechnology company that focuses on the early detection of cancer. It utilizes advanced machine learning algorithms and fragment omics to analyze fragments of cell-free DNA. The company's product is the FirstLook blood test, a laboratory-developed test designed to enhance lung cancer screening. Delfi products are used in the healthcare industry, particularly in routine clinical practice and large-scale clinical trials. The company operates across the US. Delfi is headquartered in Baltimore, Maryland, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Delfi Diagnostics Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Delfi Diagnostics Inc Company Overview
- Delfi Diagnostics Inc Company Snapshot
- Delfi Diagnostics Inc Pipeline Products and Ongoing Clinical Trials Overview
- Delfi Diagnostics Inc - Pipeline Analysis Overview
- Delfi Diagnostics Inc - Key Facts
- Delfi Diagnostics Inc - Major Products and Services
- Delfi Diagnostics Inc Pipeline Products by Development Stage
- Delfi Diagnostics Inc Ongoing Clinical Trials by Trial Status
- Delfi Diagnostics Inc Pipeline Products Overview
- Delfi Lung Cancer Screening Test
- Delfi Lung Cancer Screening Test Product Overview
- Delfi Lung Cancer Screening Test Clinical Trial
- DELFI Test 01
- DELFI Test 01 Product Overview
- DELFI Test 01 Clinical Trial
- Delfi Treatment Monitoring Test
- Delfi Treatment Monitoring Test Product Overview
- Hepatocellular Carcinoma Detection Test
- Hepatocellular Carcinoma Detection Test Product Overview
- Delfi Diagnostics Inc - Key Competitors
- Delfi Diagnostics Inc - Key Employees
- Delfi Diagnostics Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Delfi Diagnostics Inc, Recent Developments
- Apr 06, 2026: DELFI Diagnostics to Showcase Whole-Genome cfDNA Platform Advances in Cancer Detection and Monitoring at AACR 2026 Annual Meeting
- Dec 05, 2025: Preliminary Data from FANSS Study Show Potential for Blood-Based Lung Cancer Detection in Non-Smoking Population
- Nov 04, 2025: Delphi Diagnostics Announces Four Abstracts and One General Session Presentation at the San Antonio Breast Cancer Symposium
- Apr 25, 2025: Delfi Diagnostics To Present Early Detection and Advanced Cancer Monitoring Technology Updates at AACR Annual Meeting
- Nov 19, 2024: DELFI Diagnostics Selects Lahey Hospital & Medical Center to Administer New Lung Cancer Screening Test
- Oct 28, 2024: Blood Test Can Monitor the Effect of Cancer Therapy
- Oct 28, 2024: DELFI Diagnostics Working with Incendia Therapeutics to Employ Advanced Treatment Monitoring Test in a Phase 1 Clinical Trial
- Oct 22, 2024: Florida Lung Health Coalition, with Support from DELFI Diagnostics, RadNet and The American Lung Association, to Launch a Revolutionary Lung Cancer Screening Program Focused on Early Detection
- Oct 21, 2024: DELFI Diagnostics Study on Cancer Treatment Monitoring Using Fragmentomes Featured in Nature Communications
- Oct 07, 2024: Allegheny Health Network Explores Use of Promising New Blood-Based Test to Enhance Lung Cancer Detection
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Delfi Diagnostics Inc Pipeline Products and Ongoing Clinical Trials Overview
- Delfi Diagnostics Inc Pipeline Products by Equipment Type
- Delfi Diagnostics Inc Pipeline Products by Indication
- Delfi Diagnostics Inc Ongoing Clinical Trials by Trial Status
- Delfi Diagnostics Inc, Key Facts
- Delfi Diagnostics Inc, Major Products and Services
- Delfi Diagnostics Inc Number of Pipeline Products by Development Stage
- Delfi Diagnostics Inc Pipeline Products Summary by Development Stage
- Delfi Diagnostics Inc Ongoing Clinical Trials by Trial Status
- Delfi Diagnostics Inc Ongoing Clinical Trials Summary
- Delfi Lung Cancer Screening Test - Product Status
- Delfi Lung Cancer Screening Test - Product Description
- Delfi Lung Cancer Screening Test - CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung
- Delfi Lung Cancer Screening Test - Towards Individually Tailored Invitations, Screening Intervals and Integrated Co-morbidity Reducing Strategies in Lung Cancer Screening: 4-IN-THE-LUNG-RUN
- DELFI Test 01 - Product Status
- DELFI Test 01 - Product Description
- DELFI Test 01 - An Open-Label Phase 1 Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of PRTH-101 Alone or in Combination with Pembrolizumab in Adults with Advanced or Metastatic Solid Tumors
- Delfi Treatment Monitoring Test - Product Status
- Delfi Treatment Monitoring Test - Product Description
- Hepatocellular Carcinoma Detection Test - Product Status
- Hepatocellular Carcinoma Detection Test - Product Description
- Delfi Diagnostics Inc, Key Employees
- Delfi Diagnostics Inc, Other Locations
- Glossary
- Delfi Diagnostics Inc Pipeline Products by Equipment Type
- Delfi Diagnostics Inc Pipeline Products by Development Stage
- Delfi Diagnostics Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Grail LLC
- Circulogene Theranostics Inc
- Biocept Inc
